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There is increasing evidence that neurotransmitters play
a crucial role in skin physiology and pathology. The
expression and production of proopiomelanocortin mole-
cules such as b-endorphin in human epidermis suggest
that an opiate receptor is present in keratinocytes. In this
paper we show that human epidermal keratinocytes
express a m-opiate receptor on both the mRNA level and
the protein level. Performing polymerase chain reaction
with cDNA libraries from human epidermal keratinocytes
gave the polymerase chain reaction products of the
expected length, which were confirmed as m-opiate recep-
tors by Southern blot analysis. Using in situ hybridization
techniques with a specific probe for m-opiate receptors
we detected the receptor in human epidermis. There was
a cytoplasmic expression in all layers of the epidermis,
Recent studies suggest that the nervous system and theskin interact directly through neuropeptides (Anselet al, 1996). Neuropeptides are able to interact withmultiple types of cells in the skin to mediate actionsimportant in skin inflammation. Thus there is possibly
not only a neuroimmunologic axis but also a neuroimmune–dermato-
logic axis. This system would operate multidirectionally between the
skin, the immune system, and the nervous system. Such interaction
may be expressed as stress-dependent neurogenic inflammation, a
frequently mentioned factor in common skin diseases like psoriasis
(Glinski et al, 1994) and atopic dermatitis (Glinski et al, 1995). The
clinical observation of aggravation of these skin diseases by psychic
stress and anxiety has been associated with anomalous neuropeptide
regulation. This emphasizes the role of the skin itself as a source and
target of classical stress factors like adrenocorticotropin and endorphins.
Of special interest is the role of epidermal keratinocytes in the
neuroimmune–dermatologic system. Human epidermal keratinocytes
express different neuropeptides, including proopiomelanocortin
(POMC) (Schauer et al, 1994). One POMC derivative is β-endorphin,
which binds with high affinity to µ-opiate receptors. There are reports
of elevation of β-endorphin concentration in skin diseases like psoriasis
(Glinski et al, 1994) or atopic dermatitis (Glinski et al, 1995). We have
therefore investigated if the major cell type in human skin, keratinocytes,
express an opioid receptor for this ligand. We found that human
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which was more distinct in the suprabasal layers.
Immunohistochemistry using the m-opiate receptor-
specific antibody indicates that epidermis expresses pro-
tein as well, and that the protein level is more elevated
in the basal layer. The correlation between the locations
of both mRNA and protein expression in skin indicates
that the m-opiate receptor has not only been transcribed
but also has a specific function. To prove a function of
the receptor we performed a functional assay using skin
organ cultures from human skin transplants. After 48 h
incubation with Naloxone or b-endorphin the expression
of the m-opiate receptor in epidermis was significantly
downregulated compared with the control. These results
show that a functional receptor indeed exists in human
epidermis. Key words: human keratinocytes/m-opiate receptor.
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epidermal keratinocytes indeed express a µ-opiate receptor at both the
mRNA level and the protein level.
MATERIALS AND METHODS
Polymerase chain reaction (PCR) and Southern blot analysis Two pairs
of µ-opiate receptor-specific primers were designed. The first pair is TM1a:
CATCATGGCCCTCTACTCTATC (position 418–440 of HSMOR1X) and
E2: GGACCCCTGCCTGTATTTTGT (position 851–830 of HSMOR1X);
the second pair is MSt1f: GTCAGTACCATGGACAGCAG (position 203–223
of HSMOR1X) and Mst1r: CTGTTAGGGCAACGGAGCAG (position 1418–
1398 of HSMOR1X). The PCR reaction was conducted on a human
keratinocyte cDNA library (Clontech, Palo Alto, CA). The reaction was carried
out under the following conditions: 94°C 49, 1 cycle; 94°C 19, 37°C 19, 72°C
19, 10 cycles; 94°C 19, 55°C 19, 72°C 19, 35 cycles. The PCR products were
analyzed on a 1.0% agarose gel and were blotted onto membranes. The blots
were hybridized with digoxigenin-labeled µ-opiate receptor-specific probe and
detected using NBT/BCIP substrate color reaction. The southern hybridization
probe was made by generating a 228 nt long PCR fragment (position 457–685
of RNMORA) from the rat MOR-1 clone, which is 93% identical with
human probe. A similar PCR reaction and Southern blot were conducted on
cDNA made from mRNA isolated from cultured human keratinocytes using
the guanidinium thiocyanate method (Chirgwin et al, 1979) (Pharmacia Biotech,
Uppsala, Sweden). Human epidermal keratinocytes were obtained from normal
human foreskins. The keratinocytes were cultured according to Grando et al
(1993). After one passage the keratinocytes were used to extract the mRNA.
Additionally mRNA was isolated from rat brain using an extraction kit based
on the guanidinium thiocyanate method (Pharmacia Biotech, Uppsala, Sweden).
In situ hybridization The digoxigenin-labeled riboprobes were generated
from the rat MOR-1 clone (a gift from Prof. H. Loh, Department of
Pharmacology, University of Minnesota, Minneapolis, MN). The rat MOR-1
was subcloned in pBluescript II SK (1/–) phagemid and was linearized and
transcribed with T3 and T7 RNA polymerase using digoxigenin-labeled
UTP (Boehringer, Mannheim, Germany). The rat MOR-1 was subcloned in
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pBluescript II SK (1/–) phagemid and was linearized and transcribed with T3
and T7 RNA polymerase using digoxigenin-labeled UTP (Boehringer).
Normal human skin was taken from the edge of an excisional skin biopsy
during surgical operations for nevi. The biopsies were all taken from healthy
individuals without any skin diseases. Formalin-fixed, paraffin-embedded human
skin biopsies were sectioned at 5 µm. All sections were treated with proteinase
K (10 mg per ml) and were washed in 0.1 M triethanolamine buffer containing
0.25% acetic acid. Sections were covered with 25 ml of hybridization buffer
containing anti-sense or sense RNA probe. They were incubated at 42°C for
18 h in a humidified chamber. After hybridization, the slides were washed
under stringent conditions (2310 min, 13sodium citrate/chloride buffer, 0.1%
sodium dodecyl sulfate, 2310 min, 55°C, 0.2 3 sodium citrate/chloride buffer,
Figure 1. Human m-opiate receptor is present in human keratinocyte
cDNA library. PCR was conducted by using two different µ-opiate receptor
specific primer pairs. The PCR product of the left-hand lane derived from the
first primer pair, i.e., TM1a (position 418–440 of HSMOR1X) and E2 (position
851–830 of HSMOR1X); the PCR product of the right-hand lane derived
from the second primer pair, i.e., MSt1f (position 203–223 of HSMOR1X)
and Mst1r (position 1418–1398 of HSMOR1X). Southern blot analysis using
the µ-opiate receptor specific probe confirmed the identity of the PCR
fragments. The cDNA from both the human keratinocyte cDNA library and
the cultured epidermal keratinocytes gave PCR fragments with the expected
sizes at 433 nt and 1215 nt.
Figure 2. mRNA of m-opiate receptor is
expressed in normal human corporal skin
by in situ hybridization with specific RNA
probe. The paraffin-embedded skin biopsy was
hybridized with digoxigenin-labeled anti-sense
riboprobe made from rat µ-opiate receptor
clone. The hybridization was conducted at
42°C overnight and detected with NBT/BCIP
color substrate for alkaline phosphatase labeled
anti-digoxigenin antibody. (a) Positive
hybridization signal in the epidermis and
epithelial cells of dermal adnex structures; (b, c)
positive hybridization signal in cytoplasm of
epithelial cells, mostly in the suprabasal layer; (d)
negative control hybridized with sense RNA-
probe had no signal on either dermis or
epidermis. Scale bars, (a) 220 µm, (b, d) 110 µm,
(c) 37 µm.
0.1% sodium dodecyl sulfate). They were then incubated with the anti-DIG-
alkaline phosphatase (1:3000, Boehringer) for 1 h at room temperature, followed
by NBT/BCIP substrate for up to 1 h.
Immunohistochemistry The skin biopsies taken from the edge of excisional
skin were embedded in Tissue-Tek (Miles, Elkhart, IN) and immediately snap
frozen in liquid nitrogen. The frozen biopsies were cut into 6 µm sections.
The sections were first fixed in acetone and blocked with 5% normal goat
serum, 2% fish gelatin in Tris buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5)
for 1 h at room temperature. The antibody used to stain the µ-opiate receptor
was a commercially available, affinity purified, polyclonal rabbit anti-µ-opioid
receptor antibody (Pharmingen, Hamburg, Germany). This antibody was
generated from an immunogen of a 17 amino acid peptide with a sequence
that is 100% identical in the human, mouse, and rat (information from
Pharmingen). The primary antibody was incubated with sections for 1 h at
37°C whereas the controls were left in normal goat serum. After three washes
with Tris buffer, the sections were all incubated with Cy2-conjugated goat
anti-rabbit IgG (H 1 L) (Jackson Immuno Research Laboratories, West Grove,
PA) at room temperature for 30 min. The secondary antibody was tested
for minimal cross-reaction to human, mouse, and rat serum proteins. The
sections were visualized using immunofluorescence microscopy (Nikon, Diaphot
300, Tokyo, Japan).
Opiate receptor expression in human skin organ culture Skin grafts of
about 0.5 mm thickness were obtained by a dermatome from the upper leg of
an individual. To standardize the tissue volume and thereby the cell mass of
cultured skin fragments, only punches of 4 mm diameter were used. Several
randomized 4 mm skin punches per experimental group were placed on Anocell
10 mm tissue culture inserts (Nunc, Life Technologies, Rockville, MD). These
inserts were put in a Nunclon 24 well plate containing 2 ml Dulbecco’s
modified Eagle’s medium (with Glutamax-I, Life Technologies) supplemented
with 10% fetal bovine serum and 50 µg gentamicin (Life Technologies) per ml.
After addition of 10 µM β-endorphin or 100 µM naltrexone separately, the
organ cultures were incubated for 48 h at 37°C in 5% CO2 and 100% humidity.
As control we incubated skin organ cultures in the culture medium only. At
the end of the incubation period the organ culture pieces were embedded in
Tissue-Tek and immediately snap frozen in liquid nitrogen. This method of
functional assays with skin organ cultures is adapted from the methods of Paus
et al (1994). Finally we performed immunohistochemistry with the affinity
purified, polyclonal rabbit anti-µ-opioid receptor antibody (Pharmingen) and
used Cy2-conjugated goat anti-rabbit IgG (H 1 L) (Jackson Immuno Research
Laboratories) as secondary antibody as described above.
RESULTS
mRNA of human m-opiate receptor is expressed in
keratinocytes We have conducted PCR using primers specific for
human µ-opiate receptor on both a human keratinocyte cDNA library
and cDNA made by reverse transcriptase-PCR from human foreskin
keratinocytes in culture. The cDNA from the human keratinocyte
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Figure 3. m-opiate receptor protein is
present in human epidermis. Cryosections
of normal human skin were stained with µ-
opiate receptor specific antibody. The normal
human skin cryosection (6 µm) was first blocked
with 5% normal goat serum and then incubated
with µ-opiate receptor antibody at 37°C for 1
h. The secondary antibody labeled with Cy2
was used to detect the binding sites. (a) Positive
staining of normal human scalp skin in
interfollicular epidermis and dermal adnex
structures, no specific staining of the cornified
material of the stratum corneum and in the hair
follicle. (b) Positive immunohistochemical signal
in cytoplasm of epithelial cells from normal
human scalp skin and (c) epithelial cells from
normal human corporal skin. More intense
immunostaining of the µ-opiate receptor on
the basal layer. (d) Negative control biopsy was
only exposed to the secondary fluorescence
tagged antibody. There was no specific staining
in the epidermis. Scale bars, (a) 220 µm, (b, d)
110 µm, (c) 37 µm.
cDNA library and cultured epidermal keratinocytes gave PCR frag-
ments with the expected sizes at 1215 nt and 433 nt. The specificity
of the PCR products was confirmed using Southern blot analysis with
a µ-opiate receptor-specific probe (Fig 1). The 433 nt PCR fragment
from cultured human foreskin keratinocyte cDNA was subcloned in
TA-cloning vector and sequenced. The sequence was identical with
the MOR-1 human µ-type opioid receptor. Amplification with primers
specific for human δ-opiate receptors and κ-opiate receptors gave no
PCR products. All these results suggest that there is only one type of
opiate receptor in human keratinocytes, which is identical with the µ-
opiate receptor (MOR-1) in human brain.
mRNA of m-opiate receptor is expressed in human epidermis
The expression of the µ-opiate receptor at the mRNA level in vivo
was shown by in situ hybridization experiments using paraffin-embedded
normal human corporal skin sections. To test the specificity of the
RNA probe we first performed in situ hybridization with rat brain.
Specific hybridization signal of nerve cells especially in the subcortical
zone of the brain was observed (data not shown). The positive
hybridization signal is found in the epidermis and also in epithelial
cells of dermal adnex structures such as sweat gland ducts and hair
follicles (Fig 2a). The epithelial cells in the hair follicle are hybridized
as strongly as in the epidermis. The central parts of the sebaceous
glands with the disintegrating glandular cells are negative, but the
epithelial cells of the lobes, especially at the periphery of the glands,
are positive. The epithelial cells of the secretory sweat gland ducts are
also hybridized positively. There was an expression of mRNA in all
epidermal layers, except in the corneal layer. All hybridized signals are
observed in the cytoplasmic region and there is no nuclear staining.
Although the hybridized signal tends to be dispersed throughout the
whole epidermis, it is more intense in the cells of the suprabasal region.
The endothelial cells of blood vessels were negative (Fig 2b, c).
m-opiate receptor protein is expressed in human epidermis
Immunohistochemistry experiments were carried out to give evidence
that the µ-opiate receptor is expressed on the protein level as well. To
test the specificity of the µ-opiate receptor antibody, we first performed
the immunostaining on human frontal cortex cryosections. We observed
specific staining on nerve cells and axons (data not shown). Epidermis
and dermal adnex structures expressed the µ-opiate receptor in
immunohistochemistry. The cells of the external root sheath in hair
follicle and the basal layer in the interfollicular epidermis both show
intense staining (Fig 3a); however, the staining of the hair cortex is
nonspecific, as is also observed in stratum corneum. The nonspecific
staining of horny material is often observed in immunohistochemistry
of the skin. The central glandular cells of the sebaceous glands are
negatively stained, but the peripheral epithelial cells of the glands stain
positively. The secretory portions of sweat glands also have specific
staining. These observations resemble the patterns found in in situ
hybridization described above. The staining is generally dispersed in
the epidermis and confined to the cytoplasmic region. In contrast to
the mRNA hybridization signal, there is more immunostaining of the
µ-opiate receptor on the basal layer (Fig 3b, c).
The expression of the m-opiate receptor protein decreases by
incubation with m-specific ligands We studied the regulation of
the µ-opiate receptor on protein level by exposing skin organ cultures
taken from skin transplants to an agonist and antagonist of the µ-opiate
receptor system. As control we incubated skin organ cultures in the
culture medium only. We observed a strong expression of the receptor
in the basal and suprabasal layers of the epidermis as expected (Fig 4a).
When 100 µM naltrexone, the antagonist, was added to the culture
medium, the expression of the µ-opiate receptor in epidermis was
almost totally blocked (Fig 4b) after 48 h. After 48 h incubation of
the skin organ culture with 10 µM β-endorphin the expression of the
µ-opiate receptor was significantly downregulated (Fig 4c). These
results show that the receptor can be downregulated by ligands of the
µ-opiate system and suggest that a functional active receptor indeed
exists in human epidermis.
DISCUSSION
Several observations, especially about POMC peptides, suggest the
presence of an opiate system in skin, although little data show that
opioid receptors exist in skin (Zagon et al, 1996). Our results indicate
that there is a µ-opiate receptor in skin both at the RNA and at the
protein level. We also confirmed the existence of a µ-opiate receptor
in human keratinocytes on the mRNA level. Reverse transcriptase-
PCR, amplification of cDNA, and sequencing revealed a 433 nt DNA
fragment identical to a µ-opiate receptor from human brain (MOR-
1). Southern blot analysis confirmed both PCR products. In situ
hybridization showed expression of the receptor in human epidermis,
especially in the suprabasal layers. Some expression was also observed
in the epithelial cells of adnex structures in dermis, especially sweat
gland ducts and hair follicles. Interestingly, although immunohisto-
chemistry using antibody against µ-opiate receptor resulted in strong
staining in the epidermal layer, the staining was even more pronounced
in the basal layer. This subtle difference between the expression of
mRNA and the expression of protein could be attributed to the fact
that the production of µ-opiate receptor mRNA is regulated and that
mRNA is degraded faster than the protein. Within the basal layer,
different cell types were hybridized to different extents. It will be
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Figure 4. The expression of the m-opiate receptor protein decreases
after incubation with m-specific ligands. The skin organ cultures were
incubated with different agonist and antagonist of the µ-opiate receptor system
in Dulbecco’s modified Eagle’s medium with supplements for 48 h. The
cryosections from these organ cultures were stained by µ-opiate receptor specific
antibody. (a) Control slide with skin organ culture incubated in modified Eagle’s
medium only. The receptor is expressed in basal and suprabasal layers of the
epidermis. (b) Skin organ culture incubated with 100 µM naltrexone. The
receptor in the epidermis is almost entirely downregulated. (c) Skin organ
culture incubated with 10 µM β-endorphin. The receptor in the epidermis is
significantly downregulated. The negative control biopsy for each incubation
was only exposed to the secondary antibody with fluorescence label. There was
no specific staining in the epidermis (data not shown). Scale bars, 110 µm.
interesting to investigate further whether the negative hybridizing
cells in the basal layer region are melanocytes, Langerhans cells, or
keratinocytes in a different mitotic stage.
We investigated additionally if the µ-opiate receptor is functionally
active by exposing skin organ culture to an agonist and antagonist of
the µ-opiate receptor system for 48 h. We observed a significant
downregulation of the receptor with Naltrexone, the antagonist, and
to a lesser extent with the agonist β-endorphin. It might be surprising
that the agonist and the antagonist both downregulate the receptor;
although several papers suggest that the antagonist of the opiate
receptor system, like naltrexone, can behave as opioid agonist/
antagonist (Krizanac-Bengez et al, 1995). Therefore some authors call
the µ-opiate receptor antagonist an inverse opiate agonist (Cruz et al,
1996). Further studies have to reveal the influence of different
concentrations of the agonist and antagonist on opiate receptor
expression.
In recent years several investigators have studied neuropeptides and
the expression of their receptors in human keratinocytes, including
substance P (Eedy et al, 1991) and POMC (Slominski et al, 1993a, b).
Various neurotransmitter receptors, such as those for substance P
(Pincelli et al, 1993), adrenocorticotropin (Slominski et al, 1996), and
α-MSH (Chakraborty and Pawelek, 1993) and nicotinic cholinergic
receptors (Grando et al, 1995) are found in normal and pathologic
human skin. Adrenocorticotropin and α-MSH are two of the biologic-
ally active molecules of POMC. POMC is also the precursor of β-
endorphin, an opioid peptide. Our report is the first to show that a
µ-opiate receptor, the receptor for the POMC product β-endorphin,
exists in human skin. This is an important addition to the existing list
of receptors of POMC molecules in human skin. It is also important
evidence for the interaction between skin and the neural system.
The aggravation of skin diseases like atopic dermatitis and psoriasis
by psychical stress is well known in clinical dermatology (Seville,
1989). It is known that skin and the immune system interact with
each other closely; however, there is growing evidence that the neural
system is also involved in this interaction. The µ-opiate receptor
agonist β-endorphin is significantly elevated in sera of patients with
severe atopic dermatitis (Glinski et al, 1995) and psoriasis (Glinski et al,
1994). The authors concluded in both papers that β-endorphin might
be generated predominantly in lesioned skin. Recent research in
other laboratories has indicated that human keratinocytes produce β-
endorphin after stimulation by ultraviolet radiation, IL-1α, or phorbol
ester (Wintzen et al, 1995, 1996). β-Endorphin is a specific ligand for
µ-opiate receptor and its presence would account for the existence of
µ-opiate receptor in human epidermis, which is exactly what we have
discovered. Opioid peptides are probably involved in the elicitation of
itching. Naloxone, an antagonist of the µ-opiate receptor system, has
been found to relieve itching experienced by patients with chronic
liver diseases (Bernstein and Swift, 1979) or uremia (Peer et al, 1996).
Some of the itching is due to direct release of histamine by opioid
peptides in skin. But not all of the itching can be relieved by anti-
histaminics, suggesting a direct action of opioid peptides modulating
the perception of itching.
The expression of µ-opiate receptor in human epidermal skin and
human keratinocytes suggests an important role of the opioids in the
pathology of skin diseases, in wound healing and perception of itch.
Further studies will open new prospects for skin physiology and
pathology and bring about a better understanding of the mechanism
of the interaction between the neural system and skin.
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